Trial · NCT07909265
Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma
NCT07909265, Phase 2, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma. Trials, record NCT07909265. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07909265
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma
- NCT number
- NCT07909265
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 54 participants, estimated
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Clear Cell Renal Cell Carcinoma
- Interventions
- Cadonilimab,Lenvatinib
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate(ORR) | Every 6 weeks (±5 days) from first dose (C1D1) until disease progression or end of treatment, assessed up to approximately 24 months. | Proportion of participants achieving a Complete Response (CR) or Partial Response (PR) according to RECIST V1.1 criteria. |
| Secondary | Progression-Free Survival (PFS) | Tumor assessments every 6 weeks (±5 days) until progression, death, or end of follow-up, assessed up to approximately 24 months. | Time from date of first dose to the first documented disease progression per RECIST V1.1 or death from any cause. |
| Secondary | Overall Survival (OS) | Every 3 months via telephone from first dose until death or end of follow-up, assessed up to approximately 36 months. | Time from date of first dose to death from any cause. |
| Secondary | Disease Control Rate (DCR) | Every 6 weeks (±5 days) from first dose until disease progression or end of treatment, assessed up to approximately 24 months. | Proportion of participants achieving Complete Response (CR), Partial Response (PR), or Stable Disease (SD) according to RECIST V1.1 criteria. |
| Secondary | Duration of Response (DoR) | From first documented response, assessed every 6 weeks (±5 days) until progression or death, up to approximately 24 months. | Time from first documented CR or PR to first documented disease progression or death. |
| Secondary | Quality of Life assessed by EORTC QLQ-C30 | At screening, every 6 weeks during treatment, and at end of treatment, assessed up to approximately 24 months. | Change in disease-related symptoms and health-related quality of life (HRQoL) assessed by the EORTC QLQ-C30 questionnaire. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers18
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07909265
GET https://conductscience.org/api/trials/v1/NCT07909265/registered